Skye Bioscience, Inc.
SKYE
$1.83
$0.010.55%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.87M | 85.50K | 4.33M | 4.21M | 2.49M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | 0.00 | 800.00 | 400.00 | -- | 0.00 |
Total Operating Expenses | 10.67M | 4.97M | 8.41M | 6.15M | 4.09M |
Operating Income | -10.67M | -4.97M | -8.41M | -6.15M | -4.09M |
Income Before Tax | -9.75M | -3.90M | -7.89M | -5.02M | -4.42M |
Income Tax Expenses | 0.00 | -- | 8.10K | 2.00K | 0.00 |
Earnings from Continuing Operations | -9.75M | -3.90M | -7.90M | -5.02M | -4.42M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -9.75M | -3.90M | -7.90M | -5.02M | -4.42M |
EBIT | -10.67M | -4.97M | -8.41M | -6.15M | -4.09M |
EBITDA | -10.49M | -4.90M | -8.38M | -6.12M | -4.06M |
EPS Basic | -0.24 | -0.10 | -0.20 | -0.18 | -0.36 |
Normalized Basic EPS | -0.15 | -0.07 | -0.13 | -0.14 | -0.23 |
EPS Diluted | -0.24 | -0.10 | -0.20 | -0.18 | -0.36 |
Normalized Diluted EPS | -0.15 | -0.07 | -0.13 | -0.14 | -0.23 |
Average Basic Shares Outstanding | 39.97M | 38.82M | 38.67M | 28.00M | 12.40M |
Average Diluted Shares Outstanding | 39.97M | 38.82M | 38.67M | 28.00M | 12.40M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |